Get the Stockscreener App
9.00
8.70%
0.72
Pre-market:
9.55
0.55
+6.11%
Cervomed Inc stock is traded at $9.00, with a volume of 43,112.
It is up +8.70% in the last 24 hours and up +28.21% over the past month.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
See More
Previous Close:
$8.28
Open:
$8.15
24h Volume:
43,112
Relative Volume:
0.45
Market Cap:
$83.27M
Revenue:
-
Net Income/Loss:
$-6.42M
P/E Ratio:
-1.6068
EPS:
-5.6013
Net Cash Flow:
$-7.45M
1W Performance:
-9.46%
1M Performance:
+28.21%
6M Performance:
+20.32%
1Y Performance:
-7.22%
1-Day Range:
$8.15
$9.02
1-Week Range:
$7.80
$10.00
52-Week Range:
$1.80
$16.94
Cervomed Inc Stock (CRVO) Company Profile
Name
Cervomed Inc
Sector
Industry
Phone
(617) 744-4400
Address
20 PARK PLAZA, BOSTON
Compare CRVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
9.00 | 76.61M | 0 | -6.42M | -7.45M | -5.6013 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Dec-17-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-11-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-11-24 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Dec-10-24 | Downgrade | D. Boral Capital | Buy → Hold |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Dec-05-24 | Initiated | H.C. Wainwright | Buy |
| Sep-18-24 | Initiated | Chardan Capital Markets | Buy |
| Jul-26-24 | Initiated | Morgan Stanley | Overweight |
| Feb-15-24 | Initiated | Canaccord Genuity | Buy |
| Nov-17-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-21-18 | Initiated | H.C. Wainwright | Buy |
View All
Cervomed Inc Stock (CRVO) Latest News
Why CervoMed Inc. (DP8) stock is a strong analyst pickEarnings Performance Report & Risk Managed Trade Strategies - Newser
CervoMed’s DLB drug shows promise in phase 2b trial - Investing.com
Cervomed (CRVO) Unveils Promising Phase 2b Trial Results for Nef - GuruFocus
CervoMed stock soars after promising dementia drug trial results - Investing.com
CervoMed Inc. Reports Phase 2b RewinD-LB Trial Results for Neflamapimod, Showing Significant Improvements in Dementia with Lewy Bodies Patients - Quiver Quantitative
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies - GlobeNewswire Inc.
How rising interest rates impact CervoMed Inc. stockPortfolio Value Report & Safe Swing Trade Setups - Newser
Is CervoMed Inc. stock attractive after correctionJuly 2025 Action & Fast Exit and Entry Strategy Plans - Newser
What RSI levels show for CervoMed Inc. (DP8) stockPortfolio Update Report & Low Drawdown Investment Strategies - Newser
Why CervoMed Inc. (DP8) stock stays undervaluedM&A Rumor & Short-Term High Return Strategies - Newser
CervoMed's (CRVO) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
CervoMed (CRVO) Maintains Buy Rating with Target Price of $31 | - GuruFocus
CervoMed (CRVO) Unveils Promising Phase 2b Trial Results for Alz - GuruFocus
Neflamapimod reduces key neurodegeneration markers in DLB study By Investing.com - Investing.com UK
CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB) - Sahm
How CervoMed Inc. (DP8) stock gains from tech spending2025 Volume Leaders & Free Real-Time Volume Trigger Notifications - Newser
Will CervoMed Inc. (DP8) stock benefit from Fed rate cutsShare Buyback & AI Powered Market Entry Ideas - Newser
What analyst consensus says on CervoMed Inc. stockRecession Risk & Free Fast Gain Swing Trade Alerts - BỘ NỘI VỤ
CervoMed Inc. (CRVO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates - ADVFN
CervoMed Inc Stock Analysis and ForecastVolume Profile Analysis & Explosive Profit Growth - earlytimes.in
CervoMed Inc. to Present Phase 2b Trial Results of Neflamapimod for Dementia with Lewy Bodies at CTAD Conference - Quiver Quantitative
CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference - Sahm
CervoMed Executives Make Bold Moves with Major Stock Purchases! - TipRanks
Will CervoMed Inc. stock outperform Nasdaq indexWeekly Gains Summary & Free Technical Pattern Based Buy Signals - newser.com
CervoMed Inc. Stock (CRVO) Opinions on Insider Buying and Clinical Trial Progress - Quiver Quantitative
CervoMed Inc. stock retracement – recovery analysisChart Signals & Smart Money Movement Tracker - newser.com
Will CervoMed Inc. (DP8) stock deliver compounding returns2025 Top Decliners & Verified Swing Trading Watchlist - newser.com
CervoMed Inc.: Chief commercial officer Winton buys $41k in CRVO - Investing.com Australia
CervoMed CEO Alam buys shares worth $182,736 By Investing.com - Investing.com Australia
Elder William buys CervoMed (CRVO) stock worth $29,250 By Investing.com - Investing.com Canada
Insider Buying: Matthew Winton Acquires Additional Shares of Cer - GuruFocus
Gregoire Sylvie buys CervoMed (CRVO) shares worth $182,736 By Investing.com - Investing.com Canada
CervoMed Inc.: Chief commercial officer Winton buys $41k in CRVO By Investing.com - Investing.com South Africa
Elder William buys CervoMed (CRVO) stock worth $29,250 - Investing.com
CervoMed CEO Alam buys shares worth $182,736 - Investing.com India
Tools to monitor CervoMed Inc. recovery probabilityJuly 2025 Recap & AI Based Trade Execution Alerts - newser.com
[Form 4] CervoMed Inc. Insider Trading Activity - Stock Titan
How to integrate CervoMed Inc. into portfolio analysis toolsMarket Growth Summary & Real-Time Chart Breakout Alerts - newser.com
CervoMed Inc. stock trend outlook and recovery pathTake Profit & Fast Exit/Entry Strategy Plans - newser.com
Cervomed Inc Stock (CRVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):